論文の公開元へ

書き出し

Refer/BibIX

RIS

BibTeX

TSV

IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis

中西雄広島大学

2021.08.26

概要

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fibrosing interstitial pneumonia of unknown cause, characterized by persistently progressive fibrosis of the lung interstitium that results in irreversible destruction of the alveolar structure [1]. The median survival
of IPF patients has been reported to be approximately 3 years [1]. The clinical course of IPF
varies widely from extremely rapid progression to relatively stable [2].
Pirfenidone and nintedanib have been approved as effective antifibrotic agents for IPF,
although their efficacy is limited to modification of the extent of pulmonary functional deterioration [3–7]. With no available treatment option that can restore the deteriorated pulmonary
function, early diagnosis of IPF as well as accurate prediction of disease progression are quite
important for the clinical management of IPF [8, 9].
Biomarkers are commonly defined as objectively measurable indicators of the physiological
and/or pathological processes of the organs or the response to therapeutic interventions [10].
For the reasons described above, substantial efforts have been made to identify a biomarker for
IPF that can support the diagnosis, prognosis prediction, and the assessment of response to
treatment [11]. We have previously performed gene expression analysis and have identified
several molecules as potential biomarkers for IPF [12]. Among these, we focused on interleukin-18 binding protein (IL-18BP), which is known to be a decoy receptor for IL-18 [13]. In
past reports, IL-18 was upregulated in patients with IPF and the lungs of bleomycin (BLM)injured mice [14–16], but the role of IL-18BP, which is a natural antagonist of IL-18, is still
unknown. Recently, it was reported that administration of IL-18BP to a BLM-injury model
improved lung fibrosis [14, 17], but the trend of IL-18BP secreted in vivo is unclear. Therefore,
the present study was conducted to clarify whether IL-18BP can serve as a diagnostic and/or
prognostic biomarker for IPF. ...

論文の公開元へ

この論文で使われている画像

参考文献

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT

statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J

Respir Crit Care Med. 2011; 183: 788–824. https://doi.org/10.1164/rccm.2009-040GL PMID: 21471066

Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med. 2011; 183: 431–40. https://doi.org/10.1164/rccm.201006-0894CI PMID:

20935110

King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial

of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2083–92. https://

doi.org/10.1056/NEJMoa1402582 PMID: 24836312

Richeldi L. Treatments for idiopathic pulmonary fibrosis. N Engl J Med. 2014; 371: 783. https://doi.org/

10.1056/NEJMc1407776

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2071–82. https://doi.org/10.1056/

NEJMoa1402584 PMID: 24836310

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in

patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (London,

England). 2011; 377: 1760–9. https://doi.org/10.1016/S0140-6736(11)60405-4 PMID: 21571362

Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of

pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040–

7. https://doi.org/10.1164/rccm.200404-571OC PMID: 15665326

Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, et al. Efficacy of pirfenidone in

patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016; 48:

843–51. https://doi.org/10.1183/13993003.01966-2015 PMID: 27471208

Aravena C, Labarca G, Venegas C, Arenas A, Rada G. Pirfenidone for Idiopathic Pulmonary Fibrosis: A

Systematic Review and Meta-Analysis. PLoS One. 2015; 10: e0136160. https://doi.org/10.1371/

journal.pone.0136160 PMID: 26308723

10.

Guiot J, Moermans C, Henket M, Corhay J-L, Louis R. Blood Biomarkers in Idiopathic Pulmonary Fibrosis. Lung. 2017; 195: 273–280. https://doi.org/10.1007/s00408-017-9993-5 PMID: 28353114

11.

Drakopanagiotakis F, Wujak L, Wygrecka M, Markart P. Biomarkers in idiopathic pulmonary fibrosis.

Matrix Biol. 2018; 68–69: 404–421. https://doi.org/10.1016/j.matbio.2018.01.023 PMID: 29408012

12.

Horimasu Y, Ishikawa N, Taniwaki M, Yamaguchi K, Hamai K, Iwamoto H, et al. Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. BMC Med Genet. 2017; 18: 88. https://doi.org/10.1186/s12881-017-0449-9 PMID: 28821283

13.

Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol.

2013; 4: 289. https://doi.org/10.3389/fimmu.2013.00289 PMID: 24115947

14.

Zhang L-M, Zhang Y, Fei C, Zhang J, Wang L, Yi Z-W, et al. Neutralization of IL-18 by IL-18 binding protein ameliorates bleomycin-induced pulmonary fibrosis via inhibition of epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2019; 508: 660–666. https://doi.org/10.1016/j.bbrc.2018.11.129

PMID: 30527805

15.

Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H. Role of proinflammatory cytokines

IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol.

2009; 41: 661–70. https://doi.org/10.1165/rcmb.2008-0182OC PMID: 19265174

16.

Kitasato Y, Hoshino T, Okamoto M, Kato S, Koda Y, Nagata N, et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2004; 31: 619–25.

https://doi.org/10.1165/rcmb.2003-0306OC PMID: 15308504

17.

Zhang L-M, Zhang J, Zhang Y, Fei C, Wang L, Yi Z-W, et al. Interleukin-18 promotes fibroblast senescence in pulmonary fibrosis through down-regulating Klotho expression. Biomed Pharmacother. 2019;

113: 108756. https://doi.org/10.1016/j.biopha.2019.108756 PMID: 30870716

18.

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Wilson KC. The 2018 Diagnosis of Idiopathic Pulmonary

Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory. Am J Respir Crit Care Med. 2019; 200: 1089–1092. https://doi.org/10.1164/

rccm.201907-1324ED PMID: 31498684

19.

Fujita K, Ewing CM, Isaacs WB, Pavlovich CP. Immunomodulatory IL-18 binding protein is produced by

prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J cancer. 2011;

129: 424–32. https://doi.org/10.1002/ijc.25705 PMID: 20878981

20.

Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm. 2014; 2014: 165742. https://doi.org/

10.1155/2014/165742 PMID: 24733959

PLOS ONE | https://doi.org/10.1371/journal.pone.0252594 June 4, 2021

14 / 15

PLOS ONE

IL-18 BP as a prognostic biomarker for IPF

21.

Watanabe M, Horimasu Y, Iwamoto H, Yamaguchi K, Sakamoto S, Masuda T, et al. C-C Motif Chemokine

Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis. Respiration. 2019; 98: 212–220. https://doi.org/10.1159/000500576 PMID: 31416084

22.

Lee R, Reese C, Bonner M, Tourkina E, Hajdu Z, Riemer EC, et al. Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. Am J Physiol Cell Mol Physiol. 2014;

306: L736–L748. https://doi.org/10.1152/ajplung.00210.2013 PMID: 24583879

23.

Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, et al. Bleomycin-induced pulmonary

fibrosis in fibrinogen-null mice. J Clin Invest. 2000; 106: 1341–50. https://doi.org/10.1172/JCI10531

PMID: 11104787

24.

Izumi Y, Nakashima T, Masuda T, Shioya S, Fukuhara K, Yamaguchi K, et al. Suplatast tosilate reduces

radiation-induced lung injury in mice through suppression of oxidative stress. Free Radic Biol Med.

2019; 136: 52–59. https://doi.org/10.1016/j.freeradbiomed.2019.03.024 PMID: 30930296

25.

Shioya S, Masuda T, Senoo T, Horimasu Y, Miyamoto S, Nakashima T, et al. Plasminogen activator

inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis. Exp Ther Med. 2018; 16:

3070–3076. https://doi.org/10.3892/etm.2018.6550 PMID: 30214528

26.

Ha CT, Li X, Fu D, Xiao M. Circulating IL-18 Binding Protein (IL-18BP) and IL-18 as Dual Biomarkers of

Total-Body Irradiation in Mice. Radiat Res. 2016; 185: 375–83. https://doi.org/10.1667/RR14238.1

PMID: 27023262

27.

Fix C, Bingham K, Carver W. Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine. 2011; 53: 19–28. https://doi.org/10.1016/j.cyto.2010.10.002 PMID: 21050772

28.

Platis A, Yu Q, Moore D, Khojeini E, Tsau P, Larson D. The effect of daily administration of IL-18 on cardiac structure and function. Perfusion. 2008; 23: 237–42. https://doi.org/10.1177/0267659108101511

PMID: 19181757

29.

Xing S-S, Bi X-P, Tan H-W, Zhang Y, Xing Q-C, Zhang W. Overexpression of interleukin-18 aggravates

cardiac fibrosis and diastolic dysfunction in fructose-fed rats. Mol Med. 16: 465–70. https://doi.org/10.

2119/molmed.2010.00028 PMID: 20644901

30.

Yu Q, Vazquez R, Khojeini EV, Patel C, Venkataramani R, Larson DF. IL-18 induction of osteopontin

mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol. 2009; 297:

H76–85. https://doi.org/10.1152/ajpheart.01285.2008 PMID: 19429811

31.

Reddy VS, Harskamp RE, van Ginkel MW, Calhoon J, Baisden CE, Kim I-S, et al. Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB

activation. J Cell Physiol. 2008; 215: 697–707. https://doi.org/10.1002/jcp.21348 PMID: 18064631

32.

Paulukat J, Bosmann M, Nold M, Garkisch S, Ka¨mpfer H, Frank S, et al. Expression and release of IL18 binding protein in response to IFN-gamma. J Immunol. 2001; 167: 7038–43. https://doi.org/10.4049/

jimmunol.167.12.7038 PMID: 11739524

33.

Mo¨ller B, Paulukat J, Nold M, Behrens M, Kukoc-Zivojnov N, Kaltwasser JP, et al. Interferon-gamma

induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology

(Oxford). 2003; 42: 442–5. https://doi.org/10.1093/rheumatology/keg146 PMID: 12626794

34.

Veenstra KG, Jonak ZL, Trulli S, Gollob JA. IL-12 induces monocyte IL-18 binding protein expression

via IFN-gamma. J Immunol. 2002; 168: 2282–7. https://doi.org/10.4049/jimmunol.168.5.2282 PMID:

11859116

35.

Mu¨hl H, Ka¨mpfer H, Bosmann M, Frank S, Radeke H, Pfeilschifter J. Interferon-gamma mediates gene

expression of IL-18 binding protein in nonleukocytic cells. Biochem Biophys Res Commun. 2000; 267:

960–3. https://doi.org/10.1006/bbrc.1999.2064 PMID: 10673399

36.

Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates

both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001; 12:

53–72. https://doi.org/10.1016/s1359-6101(00)00015-0 PMID: 11312119

37.

Zhang L-M, Zhang J, Zhang Y, Wang L, Fei C, Yi Z-W, et al. Interleukin-18 binding protein attenuates

lipopolysaccharide-induced acute lung injury in mice via suppression NF-κB and activation Nrf2 pathway. Biochem Biophys Res Commun. 2018; 505: 837–842. https://doi.org/10.1016/j.bbrc.2018.09.193

PMID: 30301527

¨ , Toktaş M, et al. The effects of IL-18BP on mRNA expresGo¨nu¨l Y, Genc¸ A, Ahsen A, Bal A, Hazman O

sion of inflammatory cytokines and apoptotic genes in renal injury induced by infrarenal aortic occlusion.

J Surg Res. 2016; 202: 33–42. https://doi.org/10.1016/j.jss.2015.12.026 PMID: 27083945

38.

39.

Kim MS, Baek AR, Lee JH, Jang AS, Kim DJ, Chin SS, et al. IL-37 Attenuates Lung Fibrosis by Inducing

Autophagy and Regulating TGF-β1 Production in Mice. J Immunol. 2019; 203: 2265–2275. https://doi.

org/10.4049/jimmunol.1801515 PMID: 31519861

40.

Tissue expression of IL18BP—The Human Protein Atlas. [cited 15 Mar 2021]. Available: https://www.

proteinatlas.org/ENSG00000137496-IL18BP/tissue

PLOS ONE | https://doi.org/10.1371/journal.pone.0252594 June 4, 2021

15 / 15

...

参考文献をもっと見る

分野

大学

学位論文種類・取得年

言語

IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis

概要

この論文で使われている画像

関連論文